Lead Product(s) : Fenebrutinib
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fenebrutinib is an investigational oral, reversible and non-covalent Bruton’s tyrosine kinase (BTK) inhibitor that is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis (RMS).
Product Name : RG7845
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2023
Lead Product(s) : Fenebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fenebrutinib
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RO7010939 (fenebrutinib) is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, which is being investigated in adults with relapsing forms of multiple sclerosis (RMS).
Product Name : RG7845
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2023
Lead Product(s) : Fenebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fenebrutinib
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase III clinical trial programme initiated for investigational medicine fenebrutinib, designed to be a highly selective and reversible Bruton’s tyrosine kinase (BTK) inhibitor, in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS).
Product Name : RG7845
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 09, 2020
Lead Product(s) : Fenebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable